Table 3. Studies in lung cancer patients treated with resection plus low dose rate brachytherapy.
| Study | Disease | Dose | N | Local control | Survival |
|---|---|---|---|---|---|
| Chen et al31 | Stage I NSCLC | 100-120 Gy | 23 | 100% | 95% at 11 mo |
| Fleischman et al32 | Stage I-stage III | 80-200 Gy | 14 | 1 y: 71% | Median survival: 15.1 mo |
| Pisch et al33 | Stage I | 140-160 Gy | 13 | 85% | 7 of 13 patients at 4-36 mo |
| Hilaris and Martini34 | T1-T3, N2 | I-125: 160 Gy Ir-192: 30 Gy |
88 | 76% | 2 y: 51% |
Abbreviations: NSCLC, non-small cell carcinoma; I-125, iodine-125; Ir-192, iridium-192.